Market revenue in 2023 | USD 306.4 million |
Market revenue in 2030 | USD 724.1 million |
Growth rate | 13.1% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer's disease |
Fastest growing segment | Alzheimer's Disease |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 35.87% in 2023. Horizon Databook has segmented the Canada immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
Canada immunoassays for neurological biomarkers market is also driven by an increase in the adoption of immunoassay-based ELISA kits as well as approval of new products that enable faster & highly sensitive diagnosis of cardiac events.
Health Canada is primarily responsible for designing the national health policy in Canada. All IVD devices (categorized under class II, III, and IV) must possess a Medical Device License (MDL) before sale in Canada. The data is generally submitted to Health Canada.
Canadian Medicare is funded & primarily administered by 13 provinces and territories. Each territory has its own insurance plan and receives cash assistance on a per capita basis from the federal government.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada immunoassay for neurological biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Canada immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account